Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Focal segmental glomerulosclerosis market research report includes an assessment of the disease epidemiology, late- to mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Focal segmental glomerulosclerosis (FSGS). The report also analyzes the clinical and commercial landscapes of FSGS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, which is caused by diverse clinicopathological entities with different mechanisms of injury. The podocyte is the principal target of lesions, resulting in scar tissue formation on the glomeruli. They may be the target of injury through nonmechanical damages (immunologic, toxic, and viral), mechanical damages, and genetic disorders.
What are the key MoA in the focal segmental glomerulosclerosis market?
The key MoA in the focal segmental glomerulosclerosis market are Receptor Antagonist, Ion Channel Blcoker, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Inhibitor. Receptor Antagonist has the highest number of pipeline products.
Focal segmental glomerulosclerosis market, by MoA
For more MoA insights, download a free report sample
What are the key targets in the focal segmental glomerulosclerosis market?
The key targets in the focal segmental glomerulosclerosis market are Receptor, Ion Channel, Protein and Peptide, Biological, and Enzyme. Receptor has the highest number of pipeline products.
Focal segmental glomerulosclerosis market, by targets
For more target insights, download a free report sample
What are the key RoA in the focal segmental glomerulosclerosis market?
The key RoA in the focal segmental glomerulosclerosis market are Oral, Injection, and Enteral. Oral has the highest number of pipeline products.
Focal segmental glomerulosclerosis market, by RoA
For more RoA insights, download a free report sample
What are the key molecule type in the focal segmental glomerulosclerosis market?
The key molecule type in the focal segmental glomerulosclerosis market are small molecule, biologic, oligonucleotide, and polymer. Small molecule has the highest number of pipeline products.
Focal segmental glomerulosclerosis market, by molecule type
For more molecule type insights, download a free report sample
What are the key sponsors in the focal segmental glomerulosclerosis market?
Some of the key sponsors in the focal segmental glomerulosclerosis market are Goldfinch Bio, Mayo Clinic, Pfizer Inc, Dimerix Ltd, River 3 Renal Corp, Complexa Inc, and Travere Therapeutics. Goldfinch Bio and Travere Therapeutics have sponsored the largest number of clinical trials (three each) in FSGS over the past 10 years.
Focal segmental glomerulosclerosis market, by sponsors
To know more about sponsors, download a free report sample
Market report overview
Key MoA | Receptor Antagonist, Ion Channel Blcoker, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Inhibitor |
Key targets | Receptor, Ion Channel, Protein and Peptide, Biological, and Enzyme |
Key RoA | Oral, Injection, and Enteral |
Key molecule type | Small Molecule, Biologic, Oligonucleotide, and Polymer |
Key sponsors | Goldfinch Bio, Mayo Clinic, Pfizer Inc, Dimerix Ltd, River 3 Renal Corp, Complexa Inc, and Travere Therapeutics |
Scope
GlobalData’s Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key MoA in the focal segmental glomerulosclerosis market?
The key MoA in the focal segmental glomerulosclerosis market are Receptor Antagonist, Ion Channel Blcoker, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Inhibitor.
-
What are the key targets in the focal segmental glomerulosclerosis market?
The key targets in the focal segmental glomerulosclerosis market are Receptor, Ion Channel, Protein and Peptide, Biological, and Enzyme.
-
What are the key RoA in the focal segmental glomerulosclerosis market?
The key RoA in the focal segmental glomerulosclerosis market are Oral, Injection, and Enteral.
-
What are the key molecule type in the focal segmental glomerulosclerosis market?
The key molecule type in the focal segmental glomerulosclerosis market are small molecule, biologic, oligonucleotide, and polymer.
-
What are the key sponsors in the focal segmental glomerulosclerosis market?
Some of the key sponsors in the focal segmental glomerulosclerosis market are Goldfinch Bio, Mayo Clinic, Pfizer Inc, Dimerix Ltd, River 3 Renal Corp, Complexa Inc, and Travere Therapeutics.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.